These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32438971)

  • 1. Antibody-secreting macrophages generated using CpG-free plasmid eliminate tumor cells through antibody-dependent cellular phagocytosis.
    Cha EB; Shin KK; Seo J; Oh DB
    BMB Rep; 2020 Aug; 53(8):442-447. PubMed ID: 32438971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
    Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
    Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
    [No Abstract]   [Full Text] [Related]  

  • 3. Near infrared imaging of epidermal growth factor receptor positive xenografts in mice with domain I/II specific antibody fragments.
    Bernhard W; El-Sayed A; Barreto K; Gonzalez C; Fonge H; Geyer CR
    Theranostics; 2019; 9(4):974-985. PubMed ID: 30867810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.
    Overdijk MB; Verploegen S; Bögels M; van Egmond M; Lammerts van Bueren JJ; Mutis T; Groen RW; Breij E; Martens AC; Bleeker WK; Parren PW
    MAbs; 2015; 7(2):311-21. PubMed ID: 25760767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
    Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
    Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
    Sheng W; Shang Y; Li L; Zhen Y
    Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies.
    Sioud M; Westby P; Vasovic V; Fløisand Y; Peng Q
    FASEB J; 2018 Sep; 32(9):5063-5077. PubMed ID: 29913558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
    Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
    Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minicircle microporation-based non-viral gene delivery improved the targeting of mesenchymal stem cells to an injury site.
    Mun JY; Shin KK; Kwon O; Lim YT; Oh DB
    Biomaterials; 2016 Sep; 101():310-20. PubMed ID: 27315214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low generation PAMAM dendrimer and CpG free plasmids allow targeted and extended transgene expression in tumors after systemic delivery.
    Navarro G; Maiwald G; Haase R; Rogach AL; Wagner E; de Ilarduya CT; Ogris M
    J Control Release; 2010 Aug; 146(1):99-105. PubMed ID: 20438778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.
    Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y
    Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-hepatoma human single-chain Fv antibody and adriamycin conjugates with potent antitumor activity.
    Chen L; Liu YH; Li YH; Jiang Y; Xie PL; Zhou GH; Li GC
    Int Immunopharmacol; 2014 Jan; 18(1):20-6. PubMed ID: 24239629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.
    Compte M; Harwood SL; Muñoz IG; Navarro R; Zonca M; Perez-Chacon G; Erce-Llamazares A; Merino N; Tapia-Galisteo A; Cuesta AM; Mikkelsen K; Caleiras E; Nuñez-Prado N; Aznar MA; Lykkemark S; Martínez-Torrecuadrada J; Melero I; Blanco FJ; Bernardino de la Serna J; Zapata JM; Sanz L; Alvarez-Vallina L
    Nat Commun; 2018 Nov; 9(1):4809. PubMed ID: 30442944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells.
    Rai K; Takigawa N; Ito S; Kashihara H; Ichihara E; Yasuda T; Shimizu K; Tanimoto M; Kiura K
    Mol Cancer Ther; 2011 Sep; 10(9):1720-7. PubMed ID: 21712475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.
    Asano R; Watanabe Y; Kawaguchi H; Fukazawa H; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Biol Chem; 2007 Sep; 282(38):27659-65. PubMed ID: 17644522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
    Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
    Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
    Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
    Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab enhances the anti-tumor function of macrophages in an IL-6 dependent manner.
    Zhao Y; Liu X; Huo M; Wang Y; Li Y; Xu N; Zhu H
    Life Sci; 2021 Feb; 267():118953. PubMed ID: 33359746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma.
    Leoh LS; Kim YK; Candelaria PV; Martínez-Maza O; Daniels-Wells TR; Penichet ML
    J Immunol; 2018 May; 200(10):3485-3494. PubMed ID: 29654211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.